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Objective: The aim of this study is to evaluate the effect of growth hormone therapy 
(rGH) on mitochondrial function on peripheral muscle and to correlate with exercise 
capacity in subjects with severe adult growth hormone deficiency (GHD).
Design: Six months, double-blind, randomized, crossover, placebo-controlled trial of 
subcutaneous rGH in 17 patients with GHD.
Measurements: Quadriceps muscle biopsies were obtained at baseline, 3 months, and 
6 months to measure succinate dehydrogenase (SDH) to assess mitochondrial activity. 
Exercise capacity was measured with cardiopulmonary exercise testing. Lipids, glycemic 
parameters, and body fat levels were also measured.
results: Serum insulin-like growth factor 1 (IGF1) levels reduced fat mass by 3.2% 
(p < 0.05) and normalized with rGH in the active phase (p < 0.005). Patients showed an 
increase in SDH (p < 0.01) from base line that differed between placebo and rGH therapy 
treatment groups (p < 0.05): those treated by rGH followed by placebo showed a sig-
nificant increase in SDH (p < 0.001) followed by a decrease, with a significant between 
group difference at the end of 6  months (p <  0.05). No significant improvements or 
correlation with exercise capacity was found.
conclusion: Short-term rGH for 3 months normalized IGF1 levels, reduced fat mass, and 
had a significant effect on mitochondrial function, but exercise capacity was unchanged.
clinical Trial registration: Number ISRCTN94165486.
Keywords: gh deficiency, succinate dehydrogenase, cardiovascular risk factors, exercise performance, 
mitochondrial dysfunction
inTrODUcTiOn
Patients with hypopituitarism have reduced life expectancy when compared to the general population, 
mainly attributed to cerebrovascular and cardiovascular disease (1, 2). The cause of this is unclear but 
induced mitochondrial dysfunction due to increased oxidized LDL, hypertriglyceridemia, and hyper-
glycemia seen in growth hormone deficiency (GHD) may trigger an increase in mitochondrial reac-
tive oxygen species (ROS) and superoxide molecules formation. The electron transport chain found 
in the mitochondria is a major site of ROS generation, mainly in the membrane-bound complexes 
Table 1 | Patient demographics.
Patient sex age Diagnosis Time from diagnosis to entry into trial (months) Therapy
1 M 51 Post Sx: pituitary macroadenoma 15 –
2 M 64 Post Sx: microprolactinoma 13 A
3 F 48 Post Sx: pituitary macroadenoma 22 A, B
4 M 46 Post Sx: pituitary macroadenoma 23 A, E
5 F 54 Post Sx: pituitary macroadenoma 9 A, B
6 F 28 Post Sx: pituitary macroadenoma 3 B
7 F 19 Cystic prolactinoma 19 C
8 M 50 Post Sx: acromegaly 25 –
9 F 58 Post Sx: pituitary macroadenoma 40 B
10 F 36 Post Sx: prolactinoma 2 B
11 M 30 Post Sx: craniopharyngioma 27 A, B
12 F 44 Empty sella 20 C
13 M 44 Post Sx: prolactinoma 27 A, D, E
14 M 69 Post Sx and RTX: pituitary adenoma 45 A, B, E
15 M 62 Post Sx: pituitary macroadenoma 22 A, E
16 M 49 Post Sx: pituitary macroadenoma 68 A, B, E
17 M 64 Post Sx: pituitary macroadenoma 18 –
A, thyroxine 125 μg daily; B, hydrocortisone (25 mg daily); C, quinagolide (75 μg daily); D, cabergoline (0.5 mg twice weekly); E, Sustanon (250 mg thrice weekly); Sx, surgery.
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I and III, playing an important role in signaling pathways required 
for the skeletal muscle adaptation (3). Succinate dehydrogenase 
(SDH) or respiratory complex II is a crucial antioxidant enzyme 
also located in the inner mitochondrial membrane and is the only 
enzyme that participates both in the electron transport chain 
and in the citric acid cycle. SDH deficiency is associated with 
mitochondrial disorders that mainly affect organ dependant on 
oxidative metabolism such as brain, skeletal muscle, and cardiac 
muscle (4), and it is sensitive to inhibition by ROS complexes (5). 
Potentially this mitochondrial dysfunction may decrease aerobic 
capacity and endothelial dysfunction/apoptosis (5).
Diminished aerobic capacity has been identified as an addi-
tional independent risk factor for all-cause and cardiovascular 
mortality in healthy subjects without documented coronary 
artery disease (6). Maximal oxygen uptake (VO2 max) is widely 
accepted as the single best measure of cardiovascular fitness and 
maximal aerobic power and represents the maximum capacity of 
an individual’s body to use oxygen during incremental exercise. 
Studies assessing VO2max in GHD have reported a reduction 
in aerobic capacity associated with a decreased VO2max up to 
28% (7, 8) when compared with predicted values (9), indicating 
reduced cardiovascular fitness. Therefore, measures of aerobic 
performance could be used to objectively assess the functional 
response following GH replacement.
Several hormones including thyroid, sex steroids, glucocor-
ticoids, and GH influence skeletal muscle growth and function. 
The growth-promoting effects of GH are mainly mediated by 
serum insulin-like growth factor 1 (IGF1); however, available 
evidence also suggests a GH-independent IGF1 effect as the 
growth response is better when GH-deficient patients are treated 
with GH in comparison to IGF1 treatment in patients with GH 
insensitivity (10).
GH binding to its receptors modulate its effects in the mito-
chondria (11, 12) through which GH may increase mitochondrial 
oxidative capacity in the cardiac and skeletal muscle. This was 
suggested in studies in healthy subjects who received a GH infu-
sion for 14 days (13) and in older women when it was combined 
with aerobic exercise (14); therefore, this could theoretically be 
a mechanism by which GH replacement could improve muscle 
function in patients with GHD. GH stimulates the synthesis of 
IGF1 in most tissues, and although circulating IGF1 is mainly 
secreted by the liver in response to GH action, locally synthesized 
IGF1 isoforms may have an autocrine or paracrine function in 
the skeletal muscle (10, 15). Higher levels of ROS have also been 
reported to downregulate IGF1 signaling potentially inducing 
insulin resistance (16).
To date, it is unknown if GHD is associated with muscle 
mitochondrial dysfunction. Therefore, the aim of this study is 
to evaluate the effects of short term administration of GH on 
peripheral muscle oxidative capacity using SDH activity as a sur-
rogate marker and whether this correlated with exercise capacity 
and cardiovascular risk markers.
sUbJecTs anD MeThODs
Seventeen patients (10 males and 7 females; mean age, 48 ± 14 years) 
with hypopituitarism resulting from pituitary tumors who were 
treated with surgery, radiotherapy, or both were recruited. Severe 
GHD was confirmed by a peak GH response to insulin-induced 
hypoglycemia of less than 9 mU/L (3 ng/mL). The average time 
from diagnosis of the pituitary lesion to inclusion in the trial was 
33 months with confirmation of severe GHD 12 months prior to 
inclusion in the trial. Subjects were on stable hormone replacement 
doses for thyroid, adrenal, and testosterone deficiencies for the 
previous 6 months prior to the study and throughout the study, 
and no adjustment of the doses were needed during the study. None 
of them had been previously treated with rGH (Table 1). During 
the study period, they were instructed to follow their usual diet and 
activity. All subjects provided written consent.
This was a 6-month, double-blind, randomized, crossover, 
placebo-controlled trial of subcutaneous recombinant GH (Lilly 
rGH®, 0.4 mg/day for 12 weeks) versus placebo (sterile diluent 
containing glycerol and m-cresol, for 12  weeks). The patients 
were randomized with a random generator table and, using a 
FigUre 1 | Flow chart describing the progress of patients through the trial.
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crossover design, allocated to study group A or B. Daily rGH or 
placebo injections were prepared by a pharmacist, which was 
separate from the trial. Nine patients in one arm and eight in 
the second arm were randomized to either placebo or rGH for 
3  months before being crossed over to the second arm of the 
study following a 2-week washout period for a further 3-month 
period (Figure 1). To maintain the blinding of the study, it was 
not possible to escalate the GH dose. Compliance was moni-
tored based on counting the returned empty vials of the study 
medication.
The study followed the declaration of Helsinki guidelines and 
was approved by the Hull and East Riding ethics committee. The 
trial registration number is ISRCTN94165486.
study Measurements
At the beginning and end of each phase, following an overnight 
fast, weight and blood pressure were measured, and blood 
samples were collected. Blood pressure was measured after the 
patients had been seated quietly for at least 5 min with the right 
arm supported at heart level. Blood pressure measurements 
were performed using an automated device (NPB-3900; Nellcor 
Puritan Bennett, Pleasanton, CA, USA) during each study visit. 
Two readings were obtained at the beginning of each visit at least 
1 min apart, and the mean value was taken. Total body fat was 
measured with the bioelectrical impedance analysis technique 
using Tanita scales (Tanita, IL, USA). Fasting venous blood 
samples were collected, separated by centrifugation at 2,000  g 
for 15 min at 4°C, and the aliquots stored at −80°C within 1 h 
of collection. Plasma glucose was measured using a Synchron 
DxC analyzer (Beckman-Coulter, UK), and total cholesterol, 
triglycerides, and high-density lipoprotein cholesterol levels 
were measured enzymatically using a Syn chron LX20 analyzer 
(Beckman-Coulter, UK). IGF1 was mea s ured using a solid-phase, 
enzyme-labeled chemiluminescent immunocentric assay on an 
Immulite 2000 analytical platform (Siemens/DPC, DPC-UK, 
Llanberis, Caernarfon, UK.). IGF1 SDS measurements were 
calculated from the online calculator for the Immulite assay 
platform (http://ticemed_sa.upmc.fr/sd_score/).
Quadriceps muscle biopsies were taken to assess changes in 
SDH activity using immunohistochemistry. The biopsies were fro-
zen immediately after excision, mounted onto cork disks, frozen 
in 2-methylbutane at −196°C, and finally 12-µm sections were cut 
using a cryostat and mounted onto polysine (VWR) microscope 
slides, which were stored at −25°C until use. All samples were 
analyzed in a single batch. Thawed sections were incubated for 
1 h at 37°C in 0.5 M Sorenson’s buffer containing 0.5 M sodium 
Table 2 | Baseline values and after 3 months placebo and 3 months 
recombinant growth hormone therapy.
baseline Placebo 
(3 months)
rgh (3 months) pvalue
baseline characteristics of the subjects
Fat mass (%) 37.4 ± 9.8 37.6 ± 10.7 36.2 ± 10.4 0.58
BMI (kg/m2) 33.9 ± 5.8 34.1 ± 6.18 33.9 ± 6.2 0.48
W–H ratio 0.97 ± 0.23 0.94 ± 0.07 0.93 ± 0.05 0.41
SBP (mmHg) 134 ± 14 129 ± 15 136 ± 16 0.06
DBP (mmHg) 83 ± 10.8 77 ± 8.6 79 ± 13 0.4
Glucose(mmol/L) 5.5 ± 0.7 5.1 ± 1.05 5.1 ± 0.9 0.99
HbA1c (%) 6.08 ± 1.02 5.6 ± 0.4 5.8 ± 0.8 0.12
IGF1 ug/L 115.5 ± 47 121 ± 50 189 ± 71 <0.005
T.Chol. (mmol/L) 5.5 ± 0.7 5.6 ± 0.8 5.4 ± 0.7 0.06
TG (mmol/L) 1.6 ± 1.1 1.5 ± 0.9 1.4 ± 0.7 0.09
SDH (OD units) 0.052 ± 0.03 0.073 ± 0.02 0.093 ± 0.02 <0.05
cardiopulmonary exercise test
Peak VO2 26.2 ± 7.6 24.3 ± 6.2 24.1 ± 7.5 0.51
VE/VCO2 27.6 ± 3.9 26.9 ± 4.5 28.3 ± 5.65 0.86
AT 15.4 ± 4.2 15.2 ± 4.8 15.6 ± 5.7 0.95
Peak RER 1.1 ± 0.07 1.08 ± 0.14 1.06 ± 0.14 0.06
Exercise time (s) 691 ± 267 730 ± 245 661 ± 239 0.64
Pulse at max 
exercise
152 ± 30 154 ± 30 147 ± 26 0.9
AT, anaerobic threshold; BMI, body mass index; BP, systolic blood pressure; DBP, 
diastolic blood pressure; HbA1c, glycosylated hemoglobin; IGF1, serum insulin-
like growth factor 1; OD, optical density; RER, respiratory exchange ratio; SDH, 
succinate dehydrogenase; T.Chol., total cholesterol; TG, triglyceride; VE/VCO2, slope 
of the relation between ventilation and carbon dioxide production; VO2, peak oxygen 
consumption; W–H ratio, waist–hip ratio.
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succinate and 1  mg/mL nitroblue tetrazolium. After rinsing in 
water, the sections were fixed in formal saline and mounted in 
glycergel for optical density analysis using a light microscope 
equipped with a Cool-Snap digital camera and Image Pro plus an 
image analysis software (Media Cybernetics, Wokingham, UK). 
Four random fields of view at 100× magnification were used from 
each section. Black and white images were captured, background 
corrected, and calibrated for incident light. An average optical 
density value for each was measured.
Exercise capacity was assessed calculating the maximal oxygen 
consumption (VO2max) following cardiopulmonary exercise test, 
using a modified Bruce protocol. During the test, patients wore a 
tightly fitting facemask to which was connected a capnograph and 
a sample tube enabling online measurement of ventilation and 
metabolic gas exchange. A respiratory exchange ratio (RER) >1 
was taken to suggest a maximal effort together with an attainment 
of at least 85% of maximal heart rate.
statistical analysis
A power analysis based on the SDH could not be undertaken as 
there were no previous studies for reference. Therefore, change in 
lean body mass with rGH therapy was used as a surrogate of rGH 
treatment efficacy: for a significant reduction in total body fat, a 
sample size of eight patients in a crossover design was calculated 
giving 80% power to detect a mean decrease of 1.2% of total body 
fat, with a two-sided alpha error of 0.05 (17).
Mean changes obtained at the end of rGH treatment were 
compared with those at the end of the placebo phase, using the 
paired Student’s t-test. The data were normally distributed when 
tested with Kolmogorov–Smirnov test. Adjusting for period effect 
was carried out by the Hills-Armitage method (18). Statistical 
analysis was performed using the Stata Statistical Computer 
package (StataCorp, 2007). Results were considered statistically 
significant if the two-tailed p value was <0.05.
resUlTs
All patients completed the study and were compliant with the 
medication. Baseline study characteristics are included in Table 2. 
No significant side effects were reported other than transitory 
local discomfort following muscle biopsy; patients were assessed 
at each clinic visit.
effects on Muscle Oxidative capacity
Succinate dehydrogenase increased significantly (p < 0.001) for 
the combined arms comparing baseline just prior to rGH therapy 
to 3 months rGH therapy (0.052 ± 0.030 versus 0.093 ± 0.022, 
p < 0.0001). There was a difference between placebo and rGH-
treated groups (0.073  ±  0.02 versus 0.093  ±  0.02, p  <  0.05) 
(Figure 2).
effects on exercise capacity
No significant effects in peak oxygen consumption (peak VO2), 
slope of the relation between ventilation and carbon dioxide 
FigUre 2 | (a) Section of quadriceps muscle from a patient deficient in growth hormone at the start of the trial. Blue staining denotes the mitochondrial enzyme 
succinate dehydrogenase. (b) Section of quadriceps muscle from the same patient at the end of the trial after 3 months treatment with growth hormone. Staining as 
above.
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production (VE/VCO2), anaerobic threshold, RER, exercise 
time, or pulse at maximal exercise were noticeable (Table  2). 
There was no correlation between SDH and exercise capacity 
(p > 0.05).
effects on igF1 and cardiovascular 
Markers
Recombinant GH replacement normalized IGF1 levels within 
the reference range. The incremental difference in total body 
fat mass determined by Tanita measurement between active 
and placebo arms was calculated for each patient (placebo 
0.2 ±  0.2% versus 3.2 ±  0.3% active) and was significantly 
reduced (p < 0.05). IGF1 levels did not differ with 3 months of 
placebo therapy and normalized with 3 months rGH therapy; 
these patients were then continued on growth hormone at 
the end of this period. For those on rGH treatment that was 
started on rGH (IGF1 120 ±  51  μg/L) and crossed over to 
placebo, IGF1 levels fell to those of pretreatment after rGH 
was withdrawn (123 ±  50  μg/L, p =  0.23) before they too 
were recommenced on rGH therapy at the end of the study 
period. No significant differences were observed in body 
mass index (BMI), waist–hip ratio, blood pressure, glucose, 
HbA1c, total cholesterol, or triglycerides (Table 2). There was 
no correlation between SDH and cardiovascular risk mark-
ers (p > 0.05). IGF1 SDS scores at baseline, 3 months active, 
and then 3 months placebo were −1.21 ± 0.9, 1.29 ± 0.9, and 
−1.07 ± 1.0, respectively, for the group that had active treat-
ment first followed by placebo. IGF1 SDS scores at baseline, 
3 months placebo, and then 3 months active were −2.2 ± 1.1, 
−2.1 ±  1.2, and 0.1 ±  0.8, respectively, for the group who 
had placebo followed by active treatment. While the baseline 
IFG-1 SDS scores differed at baseline, this difference was not 
significant (p < 0.06).
DiscUssiOn
GH either directly or via an IGF1-dependant action not only 
mediates trophic effects in the skeletal muscle promoting 
muscle cell proliferation, differentiation, and survival but also 
appears to modulate protective responses on muscles exposed 
to oxidative stress (19). Patients with GHD are exposed to an 
abnormal metabolic environment that is likely to perpetuate 
high levels of ROS, downregulating IGF1-1 signaling further 
and increasing oxidative stress and mitochondrial dysfunction. 
This high gradient of superoxide molecules could disrupt the 
individual components of the mitochondrial electron transport 
chain including SDH. By administering GH, one could postulate 
that these mitochondrial abnormalities could be ameliorated, 
in addition to a more direct, positive effect on body fat and 
lipid profile.
Our study suggests that at the end of the 3-month rGH 
treatment period, SDH reflective of mitochondrial oxidative 
activity in the peripheral muscle was higher in the rGH group 
compared to the placebo group that would be in accord with 
the reduced oxidation that was seen for rGH replacement 
over a 6-week period (20). However, the increased SDH 
activity did not reflect a significant improvement in the sub-
ject’s aerobic capacity measured by VO2max that have been 
shown to occur following prolonged rGH therapy (21, 22). 
In this context, similar increases in VO2max can be achieved 
either individualizing rGH dose or using higher doses based 
on the body weight (23–26); however, a study using a similar 
dose of GH replacement reported an increase in anaerobic 
but not aerobic (VO2max) after 6  months therapy (27), due 
to evidence that GH stimulates the anaerobic and suppresses 
the aerobic energy system (28). SDH is also influenced by the 
level of physical training, i.e., lower in subjects who lead a 
sedentary life compared to those who exercise (29) intermit-
tently, continuously, or following endurance training (30, 31). 
Furthermore, the introduction of moderate exercise in patients 
with GHD can mimic the effect of GH replacement on physical 
activity (26). Therefore, it would have been of interest to have 
had placebo and rGH groups in combination with exercise to 
determine the effect of GH, exercise, or both on SDH, given 
the data that indicate that GH does not enhance muscle 
strength, power, or aerobic exercise capacity, but improves 
anaerobic exercise capacity (32). It should be noted that this 
was an obese population with a mean BMI greater than 30, 
and it is not clear if these results would be applicable to a lean 
population.
The adequacy of rGH replacement in this study was shown 
by the normalized IGF1 levels. However, this dose and/or the 
length of treatment was inadequate to improve weight, central 
obesity, and hypercholesterolemia. It has been suggested that 
patients with the most adverse lipid profile benefit the most 
following rGH replacement (33) with changes in lipid and 
body composition seen between 6 months and a year (34–37) 
and continue up to 10 years (38) and therefore not seen in this 
3-month period.
Our study has a number of limitations. This was a small study 
although offset by the crossover design. The duration of GH 
therapy was short that may have been insufficient for the full 
spectrum of cardiovascular benefit to have accrued. However, 
the effect of GH on oxidation may be seen after 6 weeks of GH 
replacement therapy and therefore 3  months treatment would 
have been sufficient for muscle mitochondrial function changes 
to be evident (20), and indeed this was seen. However, while 
IGF1 levels returned to baseline after the withdrawal of rGH, 
the washout period of 2  weeks may not have been sufficient 
between the active group changing to the placebo group so that 
the magnitude of the SDH changes may have been larger with a 
longer washout period. It should also be noted that GH therapy 
is influenced by gender, and to maintain the blinding of the study, 
there was no dose titration; therefore, the absence of dose titra-
tion could potentially influence the findings due to variability 
on GH responsiveness between men and women. A further 
limitation is that more extensive assessment of mitochondrial 
function with citrate synthase activity and cytochrome C oxidase 
activity would have been ideally performed, but this would have 
necessitated a larger biopsy than was taken to minimize subject 
discomfort.
All the patients normalized IGF1 within reference range, but 
due to the study design, it was not possible to further titrate the 
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